Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Thursday

Werewolf Therapeutics (NASDAQ:HOWL) is expected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect Werewolf Therapeutics to post earnings of ($0.43) per share for the quarter.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $1.28 on Thursday. The business has a fifty day simple moving average of $1.43 and a 200-day simple moving average of $1.88. Werewolf Therapeutics has a fifty-two week low of $1.26 and a fifty-two week high of $8.14. The firm has a market cap of $57.04 million, a price-to-earnings ratio of -0.84 and a beta of 0.36. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a report on Tuesday, November 19th. JMP Securities cut their target price on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research note on Tuesday, January 14th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.